Related Experiment Video
Updated: May 3, 2026
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
8.4K
Interleukin 23 in Crohn's disease.
Ahmet Eken1, Akhilesh K Singh, Mohamed Oukka
1*Seattle Children's Research Institute, Center for Immunity and Immunotherapies, Seattle, Washington; and †Department of Immunology, University of Washington, Seattle, Washington.
Inflammatory Bowel Diseases
|February 1, 2014
Summary
This review discusses the role of Interleukin-23 (IL-23) receptor variants and associated cytokines in Crohn's disease (CD) pathogenesis. It highlights the contributions of both T helper 17 (Th17) cells and innate lymphoid cells to disease development.
Area of Science:
- Immunology
- Gastroenterology
- Genetics
Background:
- Crohn's disease (CD) is a chronic gastrointestinal inflammatory condition with increasing incidence.
- Genetic studies link Interleukin-23 (IL-23) receptor variants to CD susceptibility or resistance.
- IL-23 signaling is crucial for experimental inflammatory bowel disease models.
Purpose of the Study:
- To review the role of IL-23 receptor and its downstream cytokines in CD pathogenesis.
- To emphasize the involvement of both T helper 17 (Th17) cells and innate lymphoid cells (ILCs) in CD etiology.
- To discuss the dual pathogenic and protective roles of IL-17A, IL-17F, IL-22, and interferon-gamma.
Main Methods:
- Literature review summarizing current research findings.
- Analysis of genetic association studies and experimental models.
- Discussion of immune cell subsets involved in IL-23 signaling.
Main Results:
- IL-23 receptor is expressed on various immune cells, including Th17 cells and ILCs.
- IL-23 stimulation induces secretion of key cytokines like IL-17A, IL-17F, IL-22, and interferon-gamma.
- Both Th17 cells and ILCs are implicated in the development of inflammatory bowel disease.
Conclusions:
- IL-23 signaling pathways are central to Crohn's disease pathogenesis.
- Innate lymphoid cells represent a significant, recently recognized factor in CD development.
- Understanding these immune mechanisms is vital for future therapeutic strategies in CD.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
35
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.6K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755